Par Drugs and Chemicals (NSE:PAR) Other Stockholders Equity: ₹997 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:PAR Par Drugs and Chemicals Ltd NSE:PAR
82 GF Score
Price ₹104.93
GF Value ₹207.98
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Par Drugs and Chemicals Other Stockholders Equity?

Par Drugs and Chemicals NSE:PAR +10.42% 82 Other Stockholders Equity is ₹997 Mil as of Mar. 2026. GuruFocus rates NSE:PAR with a GF Score™ of 82/100 and a GF Value™ of ₹207.98 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Par Drugs and Chemicals's Other Stockholders Equity for the quarter that ended in Mar. 2026 was ₹997 Mil.

Par Drugs and Chemicals's quarterly Other Stockholders Equity declined from Sep. 2025 (₹941 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹997 Mil).

Par Drugs and Chemicals's annual Other Stockholders Equity declined from Mar. 2024 (₹1 Mil) to Mar. 2025 (₹1 Mil) but then increased from Mar. 2025 (₹1 Mil) to Mar. 2026 (₹997 Mil).

Par Drugs and Chemicals Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Par Drugs and Chemicals's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Par Drugs and Chemicals Other Stockholders Equity Chart

Par Drugs and Chemicals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.04 1.04 1.04 1.04 996.80

Par Drugs and Chemicals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.04 0.00 941.28 0.00 996.80
NSE:PAR
82GF Score
Par Drugs and Chemicals Ltd NSE:PAR
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Par Drugs and Chemicals Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of ₹997 Mil mean?
Par Drugs and Chemicals (NSE:PAR) has a Other Stockholders Equity of ₹997 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Par Drugs and Chemicals and its competitors.
Is Par Drugs and Chemicals' Other Stockholders Equity too high?
Par Drugs and Chemicals' current Other Stockholders Equity is ₹997 Mil. Overall, Par Drugs and Chemicals has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Par Drugs and Chemicals' Other Stockholders Equity compare to ZTS and UTHR?
Par Drugs and Chemicals' Other Stockholders Equity of ₹997 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Par Drugs and Chemicals and its competitors. Par Drugs and Chemicals's current Other Stockholders Equity is ₹997 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Par Drugs and Chemicals stock overvalued right now?
Based on GuruFocus' analysis, Par Drugs and Chemicals (NSE:PAR) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹207.98, compared to a current price of ₹104.93 — trading 49.5% below its estimated fair value. The current Other Stockholders Equity is ₹997 Mil. Par Drugs and Chemicals' overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Par Drugs and Chemicals (NSE:PAR), the current Other Stockholders Equity is ₹997 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Par Drugs and Chemicals (NSE:PAR) Overvalued in 2026?

Based on GuruFocus' analysis, Par Drugs and Chemicals stock appears to be undervalued. The current stock price of ₹104.93 is trading 49.5% below its estimated GF Value™ of ₹207.98. GuruFocus considers Par Drugs and Chemicals to be Significantly Undervalued.

Key valuation signals for NSE:PAR:

  • Other Stockholders Equity: ₹997 Mil
  • GF Value™: ₹207.98 vs. price of ₹104.93 (49.5% below fair value)
  • GF Score™: 82/100 with 2 warning signs

No single metric tells the full story. See the NSE:PAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Par Drugs and Chemicals Business Description

Address Gotri Vasna Road, 815, Nilamber Triumph, Vadodara, GJ, IND, 390007
Par Drugs and Chemicals Ltd manufactures active Pharmaceutical Ingredients (APIs) and fine chemicals, serving domestic and international markets. Specializing in essential magnesium-based compounds and other specialty chemicals such as Magnesium Hydroxide, Magnesium Trisilicate, Magnesium Carbonate, various grades of Magnesium Oxide, Dried Aluminum Hydroxide Gel, and Sucralfate USP, the Company produces high-quality bulk drugs used in the formulation of finished pharmaceutical products like tablets, capsules, and liquids. Committed to maintaining stringent quality standards and utilizing manufacturing processes, the Company plays a vital role in supplying reliable ingredients that ensure the safety, efficacy, and stability of pharmaceutical formulations internationally.
82GF Score

Get the complete analysis for NSE:PAR

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹104.93
Price
₹207.98
GF Value